Search

Your search keyword '"Denlinger N"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Denlinger N" Remove constraint Author: "Denlinger N" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
28 results on '"Denlinger N"'

Search Results

1. OPTIMIZATION OF A CLINICALLY VALIDATED CART FLOW ASSAY FOR COMMERCIAL ANTI-CD19 CART T-CELL THERAPY AND UNIVERSAL ASSAYS FOR DETECTION OF NOVEL CAR-T CONSTRUCTS

2. Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study

3. Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MALIGNANCIES

5. Process Development and Manufacturing: CRYOPRESERVATION METHOD OPTIMIZATION FOR PLACE-OF-CARE MANUFACTURING OF A FIRST IN HUMAN TRI-SPECIFIC CAR T-CELL THERAPY PRODUCT FOR LYMPHOID MALIGNANCIES

6. 825 - Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MALIGNANCIES

11. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib

12. Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis.

13. SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.

14. Stem-like CD8 + T cells in cancer.

15. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.

16. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.

17. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.

18. Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.

19. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

20. Recent Advances and Challenges in Cancer Immunotherapy.

21. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.

23. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.

24. CAR T-cell therapy for B-cell lymphoma.

25. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.

26. Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.

27. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

28. Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice.

Catalog

Books, media, physical & digital resources